A Prospective Observational Comparative Study of Metformin versus Myoinositol in Pcos

Abstract

Background: Polycystic Ovary Syndrome (PCOS) is a common endocrine-metabolic disorder characterized by hormonal imbalance in the ovaries, leading to symptoms such as irregular menstruation, infertility, hirsutism, and weight gain. It is also associated with insulin resistance, hyperandrogenism, and increased risk of type 2 diabetes, hypertension, and psychological issues. Management includes lifestyle modification, pharmacological treatment, and fertility interventions. Metformin and myo-inositol (MI) are commonly used therapies aimed at improving insulin sensitivity, reducing androgen levels, and enhancing fertility. This study aims to compare the effects of metformin versus myo-inositol on clinical, hormonal, metabolic, and reproductive outcomes in women with PCOS.

Objectives: 1.To evaluate and compare the effectiveness of Metformin and Myo Inositol on ovulation rate, menstrual regularity, insulin resistance, androgen levels, and metabolic profile in women with PCOS. 2. To assess the clinical advantages and tolerability of Myo-Inositol over Metformin in the management of PCOS.

Methods: Study Design: A prospective observational comparative study.

Study Setting: OBGY Department of Dr. vithalrao vikhe patil foundations medical college ahilyanagar, Maharashtra.

Study population: All women diagnosed with PCOS according to the Rotterdam criteria Sample size: 200.

Results: Both metformin and myo-inositol demonstrated improvements in insulin sensitivity, reduction in serum testosterone levels, and betterment of menstrual cycles. Improvement in ovulation rate and oocyte quality was noted in both groups, with differences observed in the degree of metabolic or reproductive improvement depending on the therapy. Detailed comparisons of clinical, hormonal, metabolic, and reproductive parameters between the two groups are presented.

Conclusions: Myoinositol offers superior overall benefits compared to Metformin in women with PCOS. Myoinositol resulted in better menstrual regulation, greater improvement in hyperandrogenic symptoms, and more favourable metabolic responses, including reduced insulin resistance. It also showed higher ovulation and conception rates with significantly fewer side effects, making it a more effective and well tolerated therapeutic option.